Description: Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
Home Page: www.peptron.co.kr
37-24, Yuseong-daero 1628 beon-gil
Daejeon,
340-54
South Korea
Phone:
82 4 2360 8880
Officers
| Name | Title |
|---|---|
| Mr. Ho-Il Choi | Chief Exec. Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 44.4298 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |